Partial
Mostly Aligned
Patient Risk:
Low
Summary
The response largely mirrors the provided label text about pregnancy-related embryo-fetal toxicity and pregnancy contraindication, including pregnancy testing and contraception timing. However, it provides additional meta-comments claiming “not_supported” due to unverifiable section/citation mapping, which is inconsistent with the label excerpts actually supplied in the prompt.
Category Scores
Accurate Statements
Adempas (riociguat) may cause embryo-fetal toxicity/fetal harm.
Supported by the provided label text in SECTION 5.1 and SECTION 8.1 (e.g., “may cause embryo-fetal toxicity” and “may cause embryo-fetal toxicity and miscarriage”).
Adempas is contraindicated during pregnancy / in females who are pregnant.
Supported by the provided label text in SECTION 5.1 (“contraindicated in females who are pregnant”) and SECTION 4.1 (“contraindicated during pregnancy”).
Pregnancy testing is required prior to treatment and monthly during treatment.
Supported by SECTION 2.3 (“Obtain pregnancy tests prior to start of treatment and monthly during treatment”).
Contraception is required during treatment and for at least one month after the last dose.
Supported by SECTION 5.1 (“at least one month after the last dose”) and SECTION 8.3 (“for 1 month after treatment with Adempas”).
Female patients must have negative pregnancy tests prior to starting, monthly during treatment, and one month after discontinuation.
Supported by SECTION 8.3 (“one month after discontinuation of treatment with Adempas”).
Unsupported Statements
The claim is “not_supported” because cited section numbers or text cannot be verified.
The prompt includes the exact label excerpts and section headers (5.1, 4.1, 2.3, 8.1, 8.3). Within the supplied information, the pregnancy/contraception/test management statements are supported. Therefore the “not_supported” conclusion is not supported by the provided label material.
Key FDA labeling section citations are likely mismatched and cannot be confirmed, so adherence cannot be confirmed.
This reasoning is not supported by the provided content because the relevant warning/contraindication and pregnancy testing/contraception excerpts are present and explicitly associated with the stated sections in the prompt.
Contradictions
Low
AI Statement
“verdict”: not_supported (overall conclusion that the pregnancy-risk/contraindication and testing/contraception claims are not supported).
Label Reference
Contradicted by the provided label excerpts in SECTION 5.1, 4.1, 2.3, 8.1, and 8.3, which support the underlying factual content of the claim.
Important Omissions
No attempt was made to evaluate additional label elements beyond pregnancy-related risk (e.g., boxed warning content text, other warnings/precautions, or other adverse reactions/monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The factual content about embryo-fetal toxicity, pregnancy contraindication, and pregnancy testing/contraception timing aligns with the provided label excerpts. The main issue is an internal assessment inconsistency (“not_supported”) rather than incorrect label facts being asserted as true.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response incorrectly concludes the claim is “not_supported” due to alleged citation uncertainty, despite the prompt providing the matching label excerpts.
Suggested Improvement
Remove or revise the meta-verdict reasoning that the label text cannot be verified; instead, base support/contradiction strictly on the supplied label excerpts for the pregnancy-related contraindication, embryo-fetal toxicity warning, pregnancy testing schedule, and contraception duration.